Ariad Gains U.S. Approval to Return Cancer Drug to Market
This article is for subscribers only.
Ariad Pharmaceuticals Inc., the cancer-drug maker that had lost about 70 percent of its value this year, will return its only product to the U.S. market after regulators approved a new prescribing and risk management plan. The shares jumped 16 percent.
Iclusig, cleared last year for certain types of leukemia, will now be approved for a smaller patient population and have post-marketing requirements including increased oversight for safety concerns and a trial testing other doses, Cambridge, Massachusetts-based Ariad said today in a statement. The company plans to start selling Iclusig again by mid-January.